Health

The cancer drug developer has closed its initial public offering after underwriters exercised the greenshoe option.

M Ventures has returned to back the cancer therapeutics developer’s $75.5m round, five years after taking part in its series A.

Data collaboration software producer Duality Technologies, e-commerce logistics provider Pandion and cybersecurity software developer Adaptive Shield each raised $30m.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The cancer drug developer has closed an initial public offering which took place alongside a $160m SoftBank-led private placement.

The small molecule drug developer has raised a series B round that brought its total funding to more than $100m.

Novartis Venture Fund returned for the small molecule drug developer’s series B round, tipping its total funding to over $100m.

The immuno-oncology drug developer’s prospective initial public offering would mark exits for Takeda, Merck Group, Ipsen and Merck & Co.

The diversified therapeutics developer has filed to go public in the United States a year after Pfizer contributed to its $310m series A round.

UChicago spinout Pyxis Oncology is aiming to raise more than $153m in its initial public offering, having set a price range of $14 to $16.

Sesame Ventures helped lazy eye treatment developer Luminopia raise $12m while UPS, Qualcomm and Mercado Libre exited courier marketplace Mandaê in a purchase by Nuvemshop.